Article Information
vol. 2 no. 100 ra80
PubMed:
Published By:
Print ISSN:
Online ISSN:
History:
- Received September 15, 2009
- Accepted November 18, 2009
- .
Copyright & Usage:
Copyright © 2009, American Association for the Advancement of Science
Research ArticleCancer Biology
Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction
- Andrea Bertotti1,
- Mike F. Burbridge2,*,
- Stefania Gastaldi1,*,
- Francesco Galimi1,*,
- Davide Torti1,*,
- Enzo Medico3,
- Silvia Giordano1,
- Simona Corso1,
- Gaëlle Rolland-Valognes4,
- Brian P. Lockhart4,
- John A. Hickman2,
- Paolo M. Comoglio1,†, and
- Livio Trusolino1,†
- 1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
- 2Cancer Research and Drug Discovery, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.
- 3Laboratory of Functional Genomics, The Oncogenomics Center, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
- 4Division of Molecular Pharmacology and Pathophysiology, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.
- ↵†To whom correspondence should be addressed. E-mail: livio.trusolino{at}ircc.it (L.T.) and paolo.comoglio{at}ircc.it (P.M.C.)
-
↵* These authors contributed equally to this work.
See allHide authors and affiliations
Science Signaling 08 Dec 2009:
Vol. 2, Issue 100, pp. ra80
DOI: 10.1126/scisignal.2000643
Vol. 2, Issue 100, pp. ra80
DOI: 10.1126/scisignal.2000643
Andrea Bertotti
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
Mike F. Burbridge
2Cancer Research and Drug Discovery, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.
Stefania Gastaldi
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
Francesco Galimi
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
Davide Torti
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
Enzo Medico
3Laboratory of Functional Genomics, The Oncogenomics Center, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
Silvia Giordano
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
Simona Corso
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
Gaëlle Rolland-Valognes
4Division of Molecular Pharmacology and Pathophysiology, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.
Brian P. Lockhart
4Division of Molecular Pharmacology and Pathophysiology, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.
John A. Hickman
2Cancer Research and Drug Discovery, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.
Paolo M. Comoglio
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
Livio Trusolino
1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
